Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae

A method for prophylaxis, treatment or amelioration of infection with K. pneumoniae, comprising administering to an individual in need thereof a therapeutically effective amount of an antibody analogue, which specifically binds to a polypeptide consisting of

• a) an amino acid sequence SEQ ID NO:
• 25, or
• b) an amino acid sequence, which is a fragment of SEQ ID NO:
• 25 consisting of residues 35-790 or residues 450-790 or residues 35-450, wherein the antibody analogue is selected from an Fab or an F(ab′)2, and an scFV,
• wherein, the antibody analogue is obtained by immunizing an animal with a protein comprising SEQ ID NO:25 or residues 35-790 or residues 450-790 of SEQ ID NO:25, isolating B-cells that bind SEQ ID NO:
• 25 or residues 35-790 or residues 450-790 of SEQ ID NO:25 from the animal, and using said B-cells in the production of the antibody analogue, which in useful in conferring passive immunity against K. pneumoniae in the individual.

A method for treatment or amelioration of infection with K. pneumoniae in an individual in need thereof, comprising effecting, in the individual, that a therapeutically effective amount of antibodies binds to pneumoniae protein, wherein the antibodies have been induced by a polypeptide constituted by residues 35-790 in SEQ ID NO:

• 25 or residues 450-790 in SEQ ID NO:
• 25 or residues 35-450 in SEQ ID NO:
• 25, wherein, the antibodies are obtained by immunizing an animal with a protein comprising SEQ ID NO:25 or residues 35-790 or residues 450-790 of SEQ ID NO:25, isolating B-cells or antibodies that bind SEO ID NO:
• 25 or residues 35-790 or residues 450-790 of SEQ ID NO:25 from the animal, and either using said B-cells in the production of the antibodies or using the antibodies isolated, where said antibodies are useful in conferring passive immunity against K. pneumoniae in the individual.

A method for treatment or amelioration of infection with K pneumoniae, comprising administering to an individual in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of monoclonal antibodies that bind to K. pneumoniae protein, wherein the monoclonal antibodies have been induced by a polypeptide consisting of amino acid sequence SEQ ID NO:

• 25, a polypeptide constituted by residues 35-790 in SEQ ID NO:
• 25, a polypeptide constituted by residues 450-790 in SEQ ID NO:
• 25, or a polypeptide constituted by residues 35-450 in SEQ ID NO:
• 25, an immunological adjuvant, and optionally a pharmaceutically acceptable carrier, wherein, the monoclonal antibody is obtained by immunizing an animal with a protein comprising SEQ ID NO:25 or residues 35-790 or residues 450-790 or residues 35-450 of SEQ ID NO:25, isolating B-cells that bind SEQ ID NO:
• 25 or residues 35-790 or residues 450-790 or residues 35-450 of SEQ ID NO:25 from the animal, and using said B-cells in the production of the monoclonal antibody, which is useful in conferring passive immunity against K. pneumoniae in the individual.